{"altmetric_id": 86509806, "counts": {"readers": {"citeulike": "0", "mendeley": "15", "connotea": "0"}, "total": {"posts_count": 49}, "twitter": {"unique_users_count": 15, "posts_count": 19}, "news": {"unique_users_count": 19, "unique_users": ["seeking_alpha", "digital_journal", "marketscreener", "ariva", "ticker_tech", "crwe_world", "tcmnet_com", "stockwatch", "pr_newswire", "morning_star", "finanzen", "wfmz_tv_69", "finanzen_ch", "benzinga", "kpvi", "it_news_online", "profitquotes_com", "biospace", "gurufocus"], "posts_count": 30}}, "citation": {"altmetric_jid": "532721422a83ee84788b4567", "authors": ["Haun, Brien K.", "Lai, Chih-Yun", "Williams, Caitlin A.", "Wong, Teri Ann", "Lieberman, Michael M.", "Pessaint, Laurent", "Andersen-Elyard, Hanne", "Lehrer, Axel T."], "doi": "10.1101/2020.07.24.220715", "first_seen_on": "2020-07-26T09:33:54+00:00", "issns": [], "journal": "bioRxiv", "last_mentioned_on": 1599829889, "links": ["https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1", "https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1?rss=1&utm_source=dlvr.it&utm_medium=twitter", "https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1.full.pdf", "https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1.full", "https://c212.net/c/link/?t=0&l=en&o=2912889-1&h=2785940875&u=https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1&a=available", "https://c212.net/c/link/?t=0&l=en&o=2907005-1&h=2834986765&u=https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1&a=https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1", "https://c212.net/c/link/?t=0&l=en&o=2907005-1&h=3443758938&u=https://www.biorxiv.org/content/10.1101/2020.07.24.220715v1&a=available"], "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/07/26/2020.07.24.220715.full.pdf", "pmid": "32743582", "publisher": "Cold Spring Harbor Laboratory", "title": "CoVaccine HT\u2122 adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation", "type": "article", "mendeley_url": "https://www.mendeley.com/catalogue/35f011fd-d5aa-33f0-961d-e657de022158/"}, "altmetric_score": {"score": 135.85, "score_history": {"1y": 135.85, "6m": 0, "3m": 0, "1m": 0, "1w": 0, "6d": 0, "5d": 0, "4d": 0, "3d": 0, "2d": 0, "1d": 0, "at": 135.85}, "context_for_score": {"all": {"total_number_of_other_articles": 17383690, "mean": 9.3766478976515, "rank": 170251, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 17215444, "rank_type": "exact", "sample_size": 17383690, "percentile": 99}, "similar_age_3m": {"total_number_of_other_articles": 301113, "mean": 18.27690913378, "rank": 6532, "this_scored_higher_than_pct": 97, "this_scored_higher_than": 294584, "rank_type": "exact", "sample_size": 301113, "percentile": 97}, "this_journal": {"total_number_of_other_articles": 117082, "mean": 13.854387335372, "rank": 1010, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 116095, "rank_type": "exact", "sample_size": 117082, "percentile": 99}, "similar_age_this_journal_3m": {"total_number_of_other_articles": 9227, "mean": 14.447830063943, "rank": 96, "this_scored_higher_than_pct": 98, "this_scored_higher_than": 9131, "rank_type": "exact", "sample_size": 9227, "percentile": 98}}}, "demographics": {"poster_types": {"member_of_the_public": 11, "researcher": 4}, "users": {"twitter": {"cohorts": {"Members of the public": 11, "Scientists": 4}}, "mendeley": {"by_status": {"Researcher": 5, "Student  > Master": 6, "Student  > Ph. D. Student": 2, "Student  > Bachelor": 4, "Student  > Doctoral Student": 1, "Other": 5, "Librarian": 4, "Unspecified": 1}, "by_discipline": {"Medicine and Dentistry": 16, "Social Sciences": 1, "Immunology and Microbiology": 2, "Agricultural and Biological Sciences": 1, "Nursing and Health Professions": 2, "Biochemistry, Genetics and Molecular Biology": 3, "Environmental Science": 1, "Unspecified": 1, "Arts and Humanities": 1}}}, "geo": {"twitter": {"US": 3, "IT": 1, "GB": 1, "GE": 1, "BE": 1}}}, "posts": {"twitter": [{"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "1949132852"}, "tweet_id": "1287320168620859392"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "1054460958226157568"}, "tweet_id": "1287320169530916864"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "151772758"}, "tweet_id": "1287320788303925248"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "51038556"}, "tweet_id": "1287321246456254464"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "738023789439635457"}, "tweet_id": "1287345804957511680"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "1265336030833422337"}, "tweet_id": "1287481126064254976"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "1244711417657376768"}, "tweet_id": "1287543122352906240"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1287727858971009026"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1287727880718426112"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "85734409"}, "tweet_id": "1288077952966709248"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "1137343848278106112"}, "tweet_id": "1288180460766584835"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "1137343848278106112"}, "tweet_id": "1288191352082182145"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "43778632"}, "tweet_id": "1288226152302235648"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "1137343848278106112"}, "tweet_id": "1288381955122356225"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "235133788"}, "tweet_id": "1288429116174327808"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "914018537823449088"}, "tweet_id": "1289278265522176000"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "892120710667264001"}, "tweet_id": "1296225942692663302"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "914018537823449088"}, "tweet_id": "1296230411941679105"}, {"license": "gnip", "citation_ids": [86509806], "author": {"tweeter_id": "824162165561114624"}, "tweet_id": "1296238433296318464"}], "news": [{"title": "Soligenix: Multiple Shots On Goal, Strong Evidence Of Success, And Attractive Valuation", "url": "http://ct.moreover.com/?a=42705727931&p=1pl&v=1&x=m2wobXszZKUEOVidIbHKxA", "license": "public", "citation_ids": [59718830, 20255752, 20744782, 86509806], "posted_on": "2020-07-28T18:16:38+00:00", "summary": "With two Phase 3 assets approaching clinical trial readouts, a government-funded vaccine program including a potential COVID-19 play, and a valuation of approximately $70 million, Soligenix ( SNGX ) provides a compelling opportunity for investors.", "author": {"name": "Seeking Alpha", "url": "http://seekingalpha.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/665/normal/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}}, {"title": "Soligenix Inc. Heats Up Ahead Of Multiple Potential Catalysts During Next Four Months; Two Phase 3 Trials and CiVax COVID-19 Vaccine Program In Focus", "url": "http://ct.moreover.com/?a=42873832474&p=1pl&v=1&x=br2ZN8C4jDZACCkjewjsrw", "license": "public", "citation_ids": [86509806], "posted_on": "2020-08-19T11:51:19+00:00", "summary": "Soligenix Inc.'s (NasdaqCM: SNGX ) busy and successful 2019 has set the stage for a potentially transformative period for the company during the back half of 2020.", "author": {"name": "Digital Journal", "url": "http://www.digitaljournal.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/223/normal/image.png?1371424893"}}, {"title": "SOLIGENIX INC. : Heats Up Ahead Of Multiple Potential Catalysts During Next Four Months; Two Phase 3 Trials and CiVax COVID-19 Vaccine Program In Focus", "url": "http://ct.moreover.com/?a=42875807944&p=1pl&v=1&x=exZCkbQbx1Hrp81wMiLQbg", "license": "public", "citation_ids": [86509806], "posted_on": "2020-08-19T16:28:04+00:00", "summary": "Soligenix Inc.'s (NasdaqCM: SNGX) busy and successful 2019 has set the stage for a potentially transformative period for the company during the back half of 2020.", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax? Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989814384&p=1pl&v=1&x=LqoZ8M3alCBbdOtmrzWSvw", "license": "public", "citation_ids": [86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:30:30+00:00", "summary": "Soligenix-Aktie dauerhaft f\u00fcr 0 Euro handeln! Jetzt auf Smartbroker.de PR Newswire PRINCETON, N.J., Sept.", "author": {"name": "Ariva", "url": "http://www.ariva.de", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/907/normal/Screen_Shot_2016-01-27_at_14.41.07.png?1453905685"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989819277&p=1pl&v=1&x=va67Y2YkT1aylq3jUgXZLg", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:33:36+00:00", "summary": "Thursday, September 10, 2020, from 4:00-5:00 pm Eastern Time PRINCETON, N.J., Sept.", "author": {"name": "Ticker Tech", "url": "http://www.tickertech.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/724/normal/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}}, {"title": "SOLIGENIX : Announces Investor Webcast Event, Advantages of the CiVax Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42999488346&p=1pl&v=1&x=xKkpI3OzuTBZYevXC51qhw", "license": "public", "citation_ids": [86509806], "posted_on": "2020-09-04T14:11:07+00:00", "summary": "PRINCETON - Soligenix, Inc. (Nasdaq: SNGX) ( Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it\u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989827596&p=1pl&v=1&x=U2bhvx8JrrG5ClbefDMwvA", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:35:03+00:00", "summary": "Thursday, September 10, 2020, from 4:00-5:00 pm Eastern Time PRINCETON, N.J., Sept.", "author": {"name": "Crwe World", "url": "http://crweworld.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/344/normal/Capture_crwe.PNG?1574923200"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the \u2026", "url": "http://ct.moreover.com/?a=42990411492&p=1pl&v=1&x=qUwNQLHKCIPvTQt8d5BFRA", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T12:57:20+00:00", "summary": "] PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet\u2026", "author": {"name": "TMCnet.com", "url": "http://www.tmcnet.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/169/normal/Screen_Shot_2014-10-01_at_14.45.46.png?1412171168"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax \u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989847543&p=1pl&v=1&x=6bAxQUWPrTRy-ROB7SfOpA", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:37:51+00:00", "summary": "Thursday, September 10, 2020, from 4:00-5:00 pm Eastern Time PRINCETON, N.J., Sept.", "author": {"name": "Stockwatch", "url": "https://www.stockwatch.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/797/normal/Capture19.PNG?1576480973"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989852828&p=1pl&v=1&x=AGdOEgg7KpKdhDMn7gVknA", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:30:00+00:00", "summary": ", from 4:00-5:00 pm Eastern Time PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc.", "author": {"name": "PR Newswire", "url": "http://www.prnewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/545/normal/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989859009&p=1pl&v=1&x=yLrcxb2EYa6YGYEJdtEFew", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:30:00+00:00", "summary": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine Thursday, September 10, 2020, from 4:00-5:00 pm Eastern Time PR Newswire PRINCETON, N.J., Sept.", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989868812&p=1pl&v=1&x=s450IkPbgIH3LqsC1L-k8g", "license": "public", "citation_ids": [86509806], "posted_on": "2020-09-03T11:41:29+00:00", "summary": ", /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that\u2026", "author": {"name": "Finanzen", "url": "https://www.finanzen.at/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/571/normal/Capture25.PNG?1575885785"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax(TM) Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989892543&p=1pl&v=1&x=VeDmY_U7jVUHJVzQzkd12g", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:30:00+00:00", "summary": "PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ --. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need\u2026", "author": {"name": "WFMZ-TV 69", "url": "https://www.wfmz.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/256/normal/Capture_62.PNG?1567141986"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989899732&p=1pl&v=1&x=--wPTLMfvBeGyVN49qnZ1A", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:44:48+00:00", "summary": "PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet\u2026", "author": {"name": "Finanzen.ch", "url": "https://www.finanzen.ch/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/573/normal/Capture26.PNG?1575886265"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989932671&p=1pl&v=1&x=IPiOfB9aEyBN7dhz4pCLGQ", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:30:00+00:00", "summary": "PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical\u2026", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax(TM) Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42989975289&p=1pl&v=1&x=MB1erWsqaJ7hkH8KVsqcMA", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:30:00+00:00", "summary": "PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ --. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need\u2026", "author": {"name": "KPVI", "url": "https://www.kpvi.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/663/normal/Capture_kvpi.PNG?1576132656"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax(TM) Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42990004353&p=1pl&v=1&x=wFvkDwPvuukrKxAZME7-5A", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T11:58:17+00:00", "summary": "PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet\u2026", "author": {"name": "IT News Online", "url": "http://www.itnewsonline.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/005/064/normal/2.PNG?1578568075"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42990048098&p=1pl&v=1&x=nzaLn_b-8L2-YmBKeKwiLA", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T12:04:41+00:00", "summary": "Thursday, September 10, 2020, from 4:00-5:00 pm Eastern Time PRINCETON, N.J., Sept.", "author": {"name": "ProfitQuotes.com", "url": "http://www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=201908201908021405PR_NEWS_USPR_____DC29726", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/276/normal/logo7E.jpg?1567155044"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42990464484&p=1pl&v=1&x=5hVrxmuZO3u6jCn-aeW4HQ", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T00:00:00+00:00", "summary": "PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet\u2026", "author": {"name": "Biospace", "url": "http://www.biospace.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/375/normal/biospace.png?1437140433"}}, {"title": "Soligenix Announces Investor Webcast Event: Advantages of the CiVax\ufffd Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=42990783841&p=1pl&v=1&x=mGU9RR96WZkDFUaeicmhYA", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-03T13:56:45+00:00", "summary": ", from 4:00-5:00 pm Eastern Time PRINCETON, N.J., Sept. 3, 2020 /PRNewswire/ -- Soligenix, Inc.", "author": {"name": "gurufocus", "url": "https://www.gurufocus.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/591/normal/7.JPG?1576044783"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43042938366&p=1pl&v=1&x=eG-JRJvFOB36AjaUwZGxNg", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-10T11:30:00+00:00", "summary": "PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet\u2026", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "SOLIGENIX : Announces Investor Webcast Event and Presentation Today Advantages of the CiVax Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43051994245&p=1pl&v=1&x=BfFOGNF3R_Y-LekaCKCUzQ", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-11T13:11:29+00:00", "summary": "Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, released the presentation for its\u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43042968745&p=1pl&v=1&x=SUfLKJSClfh728aFnXlGhg", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-10T11:35:40+00:00", "summary": "Preclinical data supports potential for:- Broadly applicable vaccine (young, elderly, immunocompromised)- Rapid onset of immunogenicity within 7 days of the first dose- Thermostabilized vaccine (ambient storage/shipping with no need for cold chain)\u2026", "author": {"name": "Ticker Tech", "url": "http://www.tickertech.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/724/normal/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43042979928&p=1pl&v=1&x=aUupWR7AwOOZ1R-A6Z3mug", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-10T11:30:00+00:00", "summary": "Preclinical data supports potential for: - Broadly applicable vaccine (young, elderly, immunocompromised) - Rapid onset of immunogenicity within 7 days of the first dose - Thermostabilized vaccine (ambient storage/shipping with no need for cold chain\u2026", "author": {"name": "PR Newswire", "url": "http://www.prnewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/545/normal/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax? Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43043005765&p=1pl&v=1&x=jrAxO2OYaQ6ps2bjKxzYCA", "license": "public", "citation_ids": [86509806, 86509806], "posted_on": "2020-09-10T11:35:28+00:00", "summary": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax? Program for Development of a Broadly Distributed...", "author": {"name": "Ariva", "url": "http://www.ariva.de", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/907/normal/Screen_Shot_2016-01-27_at_14.41.07.png?1453905685"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43043019984&p=1pl&v=1&x=smudA3XxsJBkE5nYyHXeqg", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-10T11:44:19+00:00", "summary": "PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet\u2026", "author": {"name": "Finanzen.ch", "url": "https://www.finanzen.ch/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/573/normal/Capture26.PNG?1575886265"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43043021952&p=1pl&v=1&x=2FETERpbD0wmbEZm3KGlhQ", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-10T11:30:00+00:00", "summary": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine Preclinical data supports potential for: - Broadly applicable vaccine (young\u2026", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax(TM) Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43043072676&p=1pl&v=1&x=nS_KCPDcxelKEcDKqM5icw", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-10T11:30:00+00:00", "summary": "PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ --. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need\u2026", "author": {"name": "WFMZ-TV 69", "url": "https://www.wfmz.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/256/normal/Capture_62.PNG?1567141986"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43043115818&p=1pl&v=1&x=_r3ZTOopYDHNscOHL7ou2A", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-10T11:58:47+00:00", "summary": "Preclinical data supports potential for:- Broadly applicable vaccine (young, elderly, immunocompromised)- Rapid onset of immunogenicity within 7 days of the first dose- Thermostabilized vaccine (ambient storage/shipping with no need for cold chain)\u2026", "author": {"name": "ProfitQuotes.com", "url": "http://www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=201908201908021405PR_NEWS_USPR_____DC29726", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/276/normal/logo7E.jpg?1567155044"}}, {"title": "Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax\ufffd Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine", "url": "http://ct.moreover.com/?a=43044052703&p=1pl&v=1&x=8C97WfKOZAmAyyhSd4egCw", "license": "public", "citation_ids": [86509806, 86509806, 86509806, 86509806, 86509806], "posted_on": "2020-09-10T14:11:57+00:00", "summary": "PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet\u2026", "author": {"name": "gurufocus", "url": "https://www.gurufocus.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/591/normal/7.JPG?1576044783"}}]}, "score": 135.85, "images": {"small": "https://badges.altmetric.com/?size=64&score=136&types=mmmmmttt", "medium": "https://badges.altmetric.com/?size=100&score=136&types=mmmmmttt", "large": "https://badges.altmetric.com/?size=180&score=136&types=mmmmmttt"}}